ArticleClinical kidney journal2026
Blood pressure variability associates with mortality risk of patients with ANCA-associated vasculitis.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is associated with increased cardiovascular risk, related to persistent inflammation and endothelial dysfunction. Long-term systolic blood pressure variability (SBPV), reflecting vascular damage, may predict outcomes better than mean blood pressure (BP). We investigated the impact of BP control and visit-to-visit BP variability (VVV), on all-cause mortality in AAV patients during maintenance therapy. Methods: We retrospectively studied 95 AAV patients followed at three Italian nephrology centers. SBPV was defined as the standard deviation of ≥4 systolic BP measurements within 12 months from the first SBPV assessment. Patients were stratified by SBPV tertiles. The primary outcome was all-cause mortality. Results: Over a median follow-up of 78 months, 14 patients (14.7%) died. Deceased patients were older and had higher pulse pressure (PP) and VVV. Hypertension prevalence increased across SBPV tertiles (35%, 62%, 69%; Conclusion: In AAV patients, increased VVV was associated with all-cause mortality outperforming mean systolic BP. Further research is needed to confirm the impact of variable blood pressure on patient outcomes in AAV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.